Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18144568 | 1.00 | ALDH1A1 (0.38) | ALDH1A1GPR35ADRA2AADRA2BADRA2C | |
| SCHEMBL16843967 | 0.78 | ACHE (0.40) | ALDH1A1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL18144632 | 0.78 | ACHE (0.40) | ALDH1A1KMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL3948500 | 0.76 | PNMT (0.44) | ALDH1A1ADRA2APNMTHSD17B10KMT2A | |
| SCHEMBL20786046 | 0.76 | PNMT (0.44) | ALDH1A1ADRA2APNMTHSD17B10KMT2A | |
| SCHEMBL16823947 | 0.76 | PNMT (0.44) | ALDH1A1ADRA2APNMTHSD17B10KMT2A | |
| SCHEMBL11567309 | 0.76 | MAPT (0.37) | ALDH1A1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL8443524 | 0.73 | ALDH1A1 (0.39) | ALDH1A1GPR35ADRA2APNMTHSD17B10 | |
| SCHEMBL6999227 | 0.67 | ALDH1A1 (0.41) | ALDH1A1GPR35HSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL7001440 | 0.66 | ALDH1A1 (0.40) | ALDH1A1GPR35ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663502-B2 | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663502-B2 | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160304505-A1 | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2016-10-20 | — | — | US | disclosed |
| WO-2015095788-A1 | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304505-A1 | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | ALDH1A1 360/4885GPR35 62/4885ADRA2A 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.